|
Post by pguererro on Jun 24, 2018 11:39:20 GMT -5
Take hammer's comments and agedhippie's comments, average them together, and you probably end up with something resembling reality.
|
|
|
Post by pguererro on Jun 24, 2018 11:40:40 GMT -5
Uvula...I think u hit the nail on the head
|
|
|
Post by akemp3000 on Jun 24, 2018 12:23:38 GMT -5
Disagree...missed nail and hit thumb
|
|
|
Post by awesomo on Jun 24, 2018 12:28:04 GMT -5
As good as Dr. Kendall has appeared to be, is anyone else very disappointed he wasn't on the list of insiders buying shares recently? I mean, even the Chief Marketing Officer hired about a few weeks ago bought in.
|
|
|
Post by joeypotsandpans on Jun 24, 2018 12:44:08 GMT -5
Take hammer's comments and agedhippie's comments, average them together, and you probably end up with something resembling reality. I will take Dr. Kendall's comments, no need to listen to any others as their backgrounds and education and experience are but a pimple on his rear end. You were there and heard him don't get lost in the noise #newSOC EOM ....and for that other post regarding LLY and the "ultra fast" most likely another one of the reasons Kendall left LLY "ultra fast" .....again kudos to Mike for bringing him on, great minds think alike...again why he deserved CEO of the year award he received.
|
|
|
Post by olebob1 on Jun 24, 2018 12:50:42 GMT -5
As good as Dr. Kendall has appeared to be, is anyone else very disappointed he wasn't on the list of insiders buying shares recently? I mean, even the Chief Marketing Officer hired about a few weeks ago bought in. He said he would buy stock as soon as StuartTross (Chief People & Workplace Officer) gave him the permission to buy. I don't know if it is a time restriction or contract restriction or what. It seemed like a sincere statement. I agree that I feel better about my investment when officers in the know are buying.
|
|
|
Post by uvula on Jun 24, 2018 12:54:26 GMT -5
Beta was better but vhs won the video tape war. Now they are both dead.
I am very impressed and encouraged by Kendall. But it is too soon to declare that the pump is dead and afrezza is the standard of care.
We also have to separate afrezza the drug from mnkd the investment.
|
|
|
Post by akemp3000 on Jun 24, 2018 13:11:11 GMT -5
As good as Dr. Kendall has appeared to be, is anyone else very disappointed he wasn't on the list of insiders buying shares recently? I mean, even the Chief Marketing Officer hired about a few weeks ago bought in. A Form 4 was issued on May 16 showing David M Kendall acquiring 53,500 shares. The well isn't empty yet but it seems to be drying up for those fishing for negatives.
|
|
|
Post by joeypotsandpans on Jun 24, 2018 13:49:22 GMT -5
Beta was better but vhs won the video tape war. Now they are both dead. I am very impressed and encouraged by Kendall. But it is too soon to declare that the pump is dead and afrezza is the standard of care. We also have to separate afrezza the drug from mnkd the investment. Are you analogizing Beta/VHS to a significant treatment improvement to PWD lives? Uvula you're smarter than that, the excitement by Kendall's arrival and impact naturally causes everyone involved to expect relatively more instantaneous results regarding s/p and scripts. He and Mike et. al. have the task of overcoming what the former FDA regime saddled the drug and company with...he will and has already started that process. I believe you will acknowledge that the difference between prior mgmt. since the SNY debacle and now is night and day, in essence (other than Al's impact of course) you have to look at this company is only a little over a year old, that is the perception one has to have and leave their sentiment as a prior investor in the past as hard as that may be. It's time to move on from the past, regarding the "new Mannkind" one of my favorite lines applies...."experience isn't expensive, it's priceless"
|
|
|
Post by awesomo on Jun 24, 2018 13:52:33 GMT -5
As good as Dr. Kendall has appeared to be, is anyone else very disappointed he wasn't on the list of insiders buying shares recently? I mean, even the Chief Marketing Officer hired about a few weeks ago bought in. A Form 4 was issued on May 16 showing David M Kendall acquiring 53,500 shares. The well isn't empty yet but it seems to be drying up for those fishing for negatives. Dude, those are stock options, not purchases. Stop with the "fishing for negatives" crap. www.streetinsider.com/SEC+Filings/Form+4+MANNKIND+CORP+For%3A+May+16+Filed+by%3A+Kendall+David+M/14212942.html
|
|
|
Post by awesomo on Jun 24, 2018 13:55:45 GMT -5
As good as Dr. Kendall has appeared to be, is anyone else very disappointed he wasn't on the list of insiders buying shares recently? I mean, even the Chief Marketing Officer hired about a few weeks ago bought in. He said he would buy stock as soon as StuartTross (Chief People & Workplace Officer) gave him the permission to buy. I don't know if it is a time restriction or contract restriction or what. It seemed like a sincere statement. I agree that I feel better about my investment when officers in the know are buying. All the more reason to be concerned. The CEO, the CMO (Marketing), a BoD guy (Kresa) all bought in at the same time. Surely Dr. Kendall was given that same permission.
|
|
|
Post by akemp3000 on Jun 24, 2018 14:07:03 GMT -5
MNKD management buying stock is a nice positive but insignificant compared to Mannkind presenting positive clinical data from STAT, the topic of the thread. GLTA
|
|
|
Post by sportsrancho on Jun 24, 2018 14:13:56 GMT -5
Joey is extremely smart, he also goes to sleep and wakes up at the right time and makes no bones about it, just saying:-)) Always listen to Joey
|
|
|
Post by uvula on Jun 24, 2018 14:44:16 GMT -5
Joey is extremely smart, he also goes to sleep and wakes up at the right time and makes no bones about it, just saying:-)) Always listen to Joey Every one of the shareholders I have met is smarter than I am and a better investor also. I'm not negative. I'm just trying to keep things in perspective. I'm looking forward to partying with all of you in Hawaii. But I'm not buying my nonrefundable ticket just yet.
|
|
|
Post by BD on Jun 24, 2018 16:36:50 GMT -5
Here's flyonthewall's take:
17:22 EDT MNKD theflyonthewall.com: MannKind presents positive Afrezza clinical data from STAT, AFFINITY studies
MannKind announced that new data for Afrezza from the STAT study were released at the American Diabetes Association's 78th Scientific Sessions. The STAT study involved 60 patients with Type 1 diabetes and is the first randomized, controlled study to use continuous glucose monitoring with Afrezza. The dual primary endpoints were assessment of glucose time-in-range and postprandial glucose excursions in the 1-4 hour post-meal period. STAT study poster highlights include significantly improved all-day glucose time-in-range by an average of 1.5 hours, or 12%, significantly decreased daytime glucose variability by 17%, significantly reduced the time spent in hypoglycemia by 41% or approximately 23 minutes per day. The faster action with shorter duration profile of Afrezza when compared to rapid-acting insulin analogs may provide a flexible approach for patients to optimize post-prandial glucose control without increasing risk of hypoglycemia. MannKind also presented a late-breaking poster presenting a post-hoc analysis of a representative subset of the AFFINITY 1 study that demonstrated the use of Afrezza significantly lowers the rate of hypoglycemia in patients with Type 1 diabetes while providing non-inferior glycemic control. :theflyonthewall.com
|
|